VRCA

Business Context and Reporting Period

Verrica Pharmaceuticals Inc. (VRCA) is a therapeutics company developing and commercializing medications for dermatologic diseases, including skin cancers. Its primary commercial product is YCANTH (VP-102), approved by the FDA in July 2023 for molluscum contagiosum. The company is also advancing YCANTH for common warts and developing VP-315 for basal cell carcinoma. This report covers the quarterly period ended March 31, 2026.

Key Financial Metrics

Debt and Liquidity: The company fully settled its $50.0 million Credit Agreement with OrbiMed in November 2025 for $35.0 million. As of March 31, 2026, the company had no long-term debt outstanding but holds an R&D funding liability of $5.8 million related to a collaboration with Torii. Cash balances decreased by $9.3 million during the quarter.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 46% ($1.6 million) year-over-year. Product revenue rose to $4.3 million (from $3.4 million) due to increased unit volume. License and collaboration revenue surged to $0.7 million (from $17,000), driven by commercial supply activities with Torii.
• Expense Increases: Total operating expenses increased by $3.2 million to $14.7 million.
  • Selling, General and Administrative (SG&A): Increased by $1.1 million to $10.0 million, primarily due to commercial expansion and sales force growth.
  • Research and Development (R&D): Increased by $1.6 million to $3.9 million, largely driven by costs associated with the global Phase 3 program for common warts.
• Interest Expense Reduction: Interest expense dropped significantly to $0.2 million (from $2.2 million) following the extinguishment of the OrbiMed debt facility in late 2025.
• Stock Split: A 1-for-10 reverse stock split was effected in July 2025; all prior period share data has been adjusted to reflect this.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern within one year. The company has an accumulated deficit of $334.6 million and expects to continue incurring significant losses. It plans to address this through equity offerings, debt financing, or strategic partnerships.
• Capital Constraints: The company is subject to "baby shelf rules" under Form S-3, limiting the amount of capital it can raise via public offerings until its public float exceeds $75.0 million.
• Development Progress:
  • YCANTH (Common Warts): The global Phase 3 program with partner Torii is ongoing; the first patient was dosed in December 2025.
  • VP-315 (Basal Cell Carcinoma): The company has received FDA feedback supporting an efficient Phase 3 program and has initiated clinical and CMC activities.
  • EU Expansion: The European Medicines Agency provided positive feedback supporting a Marketing Authorization Application for YCANTH in the EU.
• Legal Proceedings: A putative class action lawsuit regarding alleged manufacturing deficiencies was certified by the court on March 4, 2026. Several derivative lawsuits have been stayed or dismissed.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $20.6 million cash balance against the projected burn rate and the timeline for securing additional funding.
• Going Concern Status: Review the specific plans and progress regarding equity or debt financing to mitigate the substantial doubt disclosure.
• Revenue Quality: Assess the sustainability of the revenue increase, noting that one customer represented approximately 92% of accounts receivable as of March 31, 2026.
• Legal Exposure: Monitor the status of the certified class action lawsuit and potential financial impact.
• Collaboration Terms: Review the R&D funding arrangement with Torii, specifically the obligation to repay half of the Phase 3 program costs and the associated liability on the balance sheet.